The American Society of Transplantation Online Transplant Infectious Diseases Library
Full Library 1,578 resources
-
CAR T-cell therapy has revolutionized the treatment of hematologic malignancies, although its use may be complicated by toxicities, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections. Invasive fungal disease (IFD) has been reported after CAR T-cell therapy, but the incidence in the absence of antifungal prophylaxis is unknown. Optimal prophylaxis strategies are widely debated. We performed a single-center retrospective...
-
This study describes the genotypic and phenotypic characterization of novel human cytomegalovirus (HCMV) genetic variants of a cohort of 94 clinically resistant HCMV patients.Antiviral-resistant mutations were detected in the UL97, UL54, and UL56 target genes of 25 of 94 (26.6%) patients. The genotype-phenotype correlation study resolved the status of 5 uncharacterized UL54 deoxyribonucleic acid polymerase (G441S, A543V, F460S, R512C, A928T) and 2 UL56 terminase (F345L, P800L) mutations...
-
PROBLEM/CONDITION: Coccidioidomycosis, histoplasmosis, and blastomycosis are underdiagnosed fungal diseases that often mimic bacterial or viral pneumonia and can cause disseminated disease and death. These diseases are caused by inhalation of fungal spores that have distinct geographic niches in the environment (e.g., soil or dust), and distribution is highly susceptible to climate changes such as expanding arid regions for coccidioidomycosis, the northward expansion of histoplasmosis, and...
-
In separate phase 2 trials, 120 patients received maribavir for cytomegalovirus (CMV) infection failing conventional therapy (trial 202) and 119 received maribavir for asymptomatic infection (trial 203). Overall, 172 cleared their CMV infection (CMV DNA <200 copies/mL) within 6 weeks.Baseline and posttreatment plasma samples were tested for mutations in viral genes UL97, UL54, and/or UL27. Selected viral mutants were phenotyped for drug susceptibility.Baseline samples revealed UL54...
-
Acute leukaemic and autologous HCT patients with resolved neutropenic fever prior to count recovery can have empiric therapy safely discontinued or de-escalated. There is an emerging role of FDG-PET/CT to support decision-making about antibiotic and antifungal use in high-risk persistent/recurrent neutropenic fever patients.
-
Toxoplasmic encephalitis (TE) is an opportunistic infection of people living with HIV or other causes of immunosuppression. For decades, the standard of care has been combination therapy with pyrimethamine and sulfadiazine (P-S) or pyrimethamine and clindamycin (P-C). However, a substantial price increase has starkly limited access to pyrimethamine. Consequently, some centers have transitioned to trimethoprim-sulfamethoxazole (TMP-SMX), an inexpensive alternative treatment. We aimed to...
-
This resource was created on August 4, 2022. View the PDF version
-
Human herpesvirus-6 (HHV-6) frequently reactivates after allogeneic stem cell transplantation (SCT). Most patients are asymptomatic and viremia often resolves without therapy; however, transplant related complications may be associated with reactivation. Multiple presentations have been attributed to HHV-6 reactivation after SCT including encephalitis. Several strategies have been trialed to reduce such risks or complications. Challenges exist with prospective monitoring strategies, and...
-
Maribavir was approved by the U.S. Food and Drug Administration in November 2021 for the treatment of adult and pediatric patients with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet. Maribavir is an oral benzimidazole riboside with potent and selective multimodal anti-CMV activity. It utilizes a novel mechanism of action which confers activity against CMV...
-
Methicillin-susceptible Staphylococcus aureus (MSSA) is a common cause of bloodstream infection (BSI) in patients with febrile neutropenia, but treatment practices vary, and guidelines are not clear on the optimal regimen.We conducted a multicenter retrospective cohort study of MSSA BSI in febrile neutropenia. We divided patients into 3 treatment groups: (1) broad-spectrum beta-lactams (ie, piperacillin-tazobactam, cefepime, meropenem); (2) narrow-spectrum beta-lactams (ie, cefazolin,...
-
Febrile neutropenia (FN) after chemotherapy is a major cause of morbidity during cancer treatment. The performance of metagenomic next-generation sequencing (mNGS) of circulating cell-free deoxyribonucleic acid from plasma may be superior to blood culture (BC) diagnostics for identification of causative pathogens. The aim of this study was to validate mNGS (DISQVER test) for the detection of pathogens in hematologic patients with FN.We collected paired whole blood specimens from central...
-
Purpose of the review Passage of the HOPE Act and the advent of direct-acting antiviral (DAA) therapies have allowed for expansion of the donor organ pool to include donors with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), thus providing new opportunities for waitlist candidates. This article provides updates on recent studies in solid organ transplantation (SOT) utilizing donors with HIV and HCV. Recent findings The first pilot studies of kidney...
-
Monkeypox virus is an emergent human pathogen. While it is less lethal than smallpox, it can still cause significant morbidity and mortality. In this review, we explore three antiviral agents with activity against monkeypox and other orthopoxviruses: cidofovir, brincidofovir, and tecovirimat. Cidofovir, and its prodrug brincidofovir, are inhibitors of DNA replication with a broad spectrum of activity against multiple families of double-stranded DNA viruses. Tecovirimat has more specific...
-
Learn more about monkeypox in the United States.
-
Statins are competitive inhibitors of 3-hydroxy-3methylglutaryl coenzyme A reductase (HMG-CoA reductase) that catalyses HMG-CoA conversion to mevalonate, a process involved in synthesizing cholesterol in humans and ergosterol in fungi. The effect of statin use on the risk of development of invasive aspergillosis (IA) in lung transplant recipients (LTRs) is not well documented.This retrospective study included LTRs from 2010 to 2017 who were followed for one-year post-transplant. Proven or...
-
Risk factors for nontuberculous mycobacteria (NTM) infections after solid organ transplant (SOT) are not well characterized. Here we aimed to describe these factors.Retrospective, multinational, 1:2 matched case-control study that included SOT recipients ≥12 years old diagnosed with NTM infection from January 1, 2008, to December 31, 2018. Controls were matched on transplanted organ, NTM treatment center, and post-transplant survival greater than or equal to the time to NTM diagnosis....
Filter by our tag
GUIDELINES
- AASLD Guidelines (9)
- AST Guidelines 2019 (44)
- ASTCT Guidelines (14)
- ECIL Guidelines (20)
- ESCMID Guidelines (25)
- IDSA Guidelines (45)
- ISHLT Guidelines (12)
- TTS Guidelines (2)
- WikiGuidelines (3)
TEXTBOOKS
CORE CURRICULUM
- INTRO LVAD AND MCSS (4)
- INTRO MALIGNANT HEME, HSCT, CAR-T (10)
- INTRO SOLID ORGAN TRANSPLANT (20)
- ORGANISMS (41)
-
SYNDROMES
(16)
- CNS (2)
- Diarrhea (3)
- Neutropenic Fever (2)
- Pneumonia (7)
- UTI (2)
ORGANISMS
-
BACTERIA
(160)
- C. difficile (25)
- Legionella (1)
- MDR GNR (37)
- MRSA (7)
- Mycoplasma and Ureaplasma (11)
- Nocardia (11)
- Non-tuberculous Mycobacteria (27)
- Syphilis (6)
- Tuberculosis (35)
- VRE (8)
-
FUNGI
(218)
- Aspergillus (57)
- Candida (41)
- Cryptococcus (29)
- Dimorphic mycoses (42)
- Mucormycosis (34)
- Pneumocystis (39)
- Rarer Fungi (23)
-
PARASITES AND PROTOZOA
(44)
- Chagas (10)
- Protozoa (12)
- Strongyloides (14)
- Toxoplasmosis (12)
-
VIRUSES
(415)
- Adenovirus (17)
- Arboviruses (7)
-
CMV
(121)
- Cell-Mediated Immunity Assays (11)
- Clinical (55)
- Cytotoxic T-Lymphocytes (1)
- Epidemiology and Risk Factors (15)
- Letermovir (26)
- Maribavir (17)
- Preemptive Therapy (7)
-
COVID-19
(45)
- Diagnosis (3)
- Fungal superinfection (2)
- GUIDELINES (9)
- Infection Prevention (3)
- Positive Donors (6)
- Positive Recipients (5)
- Treatments (18)
- Vaccination (8)
- Hepatitis A (2)
- Hepatitis B (27)
- Hepatitis C (31)
- Hepatitis D (5)
- Hepatitis E (5)
- HHV-6 (24)
- HHV-8 (4)
- HIV (31)
- HPV (5)
- HSV (4)
- Influenza (17)
- Measles (22)
- Mpox (6)
- Norovirus (8)
- Parvovirus B19 (3)
- Polyomaviruses (32)
- Respiratory Viruses (32)
- RSV (18)
- VZV (17)
- WNV (2)
DIAGNOSTICS
- Advanced Diagnostics (23)
- Fungal diagnostics (41)
- Nuclear Medicine (7)
- Parasites (3)
- Procalcitonin (1)
- Viral diagnostics (1)
DRUGS AND THERAPIES
- Antibiotics (12)
- Antifungals (66)
- Antivirals (10)
- Cytotoxic T-lymphocyte therapy (8)
- Fecal Microbiota Transplantation (12)
- Phage therapy (4)
- Stewardship (57)
PREVENTION
- Infection Control (8)
- Safe Living (22)
- Travel (10)
- Vaccination (40)
SYNDROMES AND CONDITIONS
- Cirrhotics (12)
- CNS (3)
- Cytopenias (2)
- Diarrhea (13)
- Endovascular infections (12)
- Osteomyelitis and Diabetic Foot Infection (3)
- Pneumonia (11)
- Surgical Infections (3)
- UTI (32)
SOLID ORGANS AND MCSS
- Donor (43)
- Heart (14)
- Immunosuppression (14)
- Intestinal (2)
- Kidney (32)
- Liver (53)
- Lung (70)
- LVAD (30)
- Pancreas (5)
- PEDIATRIC (43)
- Recipient (5)
- Total Artificial Heart (1)
- Vascular Composite Allograft (2)
- Xenotransplantation (3)
HEME-ONC AND CELLULAR THERAPIES
- Biologics (45)
- BMT Basics (4)
- BMT Guidelines (14)
- BMT Noninfectious (10)
- BMT-specific ID (71)
- CAR-T (22)
- CAR-T Noninfectious (6)
- GVHD (6)
- Heme malignancies (4)
- Heme-onc prophylaxis (23)
- Neutropenia (40)
- PEDIATRIC (33)
- PTLD (24)
- TK inhibitors (12)
TRANSPLANT ID TRAINING
- AST (4)
- Career Development (2)
- Fungal (4)
- Training program (7)
PATIENT EDUCATION
- COVID-19 (13)
- Food (13)
- Hygiene (7)
- Mpox (5)
- Outdoor activities (3)
- PATIENT INFORMATION SHEETS (16)
- Pets (6)
- Safer living (22)
- Selected Infections (10)
- TB (10)
- Travel (6)
- Water safety (7)
- Workplace safety (3)
JOURNAL CLUB
- 2024 (2)